Sanofi (SNY) Research & Development (2009 - 2026)

Sanofi has disclosed Research & Development across 18 years of filings, most recently posting -$2.0 billion for Q1 2026.

• Research & Development for Q1 2026 came in at -$2.0 billion, down 7.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.8 billion (down 46.03% YoY), and the FY2025 annual result was $9.1 billion, up 15.53% from the prior year.
• Research & Development came in at -$2.0 billion for Q1 2026 at Sanofi, up from -$9.1 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$1.7 billion in Q1 2022 to a low of -$9.1 billion in Q4 2025.
• The 5-year median for Research & Development is -$1.9 billion (2025), against an average of -$3.5 billion.
• Across the five-year window, Research & Development declined 0.33% in 2023 and tumbled 227.92% in 2025, its largest moves.
• Sanofi's Research & Development stood at -$6.8 billion in 2022, then fell by 2.33% to -$7.0 billion in 2023, then retreated by 12.86% to -$7.9 billion in 2024, then slipped by 15.53% to -$9.1 billion in 2025, then soared by 77.59% to -$2.0 billion in 2026.
• The last three Research & Development figures came in at -$2.0 billion (Q1 2026), -$9.1 billion (Q4 2025), and -$6.5 billion (Q3 2025), per Business Quant data.